Today's Trend
Immunovant, Inc. (NASDAQ: IMVT) shares have been moving higher as investors focus on encouraging clinical progress for IMVT-1402, which appears to be outweighing softer earnings and a small insider sale.
- Immunovant reported strong Week 16 data from its rheumatoid arthritis study of IMVT-1402, with response rates that investors viewed as supportive of the drug’s potential and the company’s broader autoimmune pipeline. Article Title
- The company said its cutaneous lupus proof-of-concept trial is fully enrolled and expects topline results in the second half of 2026, giving shareholders another potential catalyst. Article Title
- Immunovant highlighted about $902 million in cash at quarter-end, which should help fund development of IMVT-1402 and reduce near-term financing concerns. Article Title
- Truist raised its price target on IMVT to $30 from $23, but kept a Hold rating, suggesting analysts are acknowledging improved prospects while still seeing limited upside from current levels. Article Title
- The company posted a quarterly loss of $0.73 per share, wider than the $0.60 consensus estimate, though that earnings miss was largely overshadowed by the clinical update. Article Title
- Director Atul Pande sold 6,000 shares in a pre-arranged 10b5-1 transaction, which may slightly temper sentiment even though the sale was planned in advance. Article Title
Overall, Immunovant (IMVT) is being pushed up by optimism around IMVT-1402’s clinical data and upcoming trial readouts, while the earnings miss and insider selling appear to be secondary concerns.